Experts discuss the need to review current clinical guidelines in light of the need for rapid-acting treatment, especially as first-line treatments for some patients.
Experts highlight the role of NMDA and AMPA receptors in major depressive disorder (MDD) and how new therapies are targeting novel mechanisms of action.
Charles Montano, MD, and Carmen Kosicek, MSN, PMHNP-BC, review currently available treatment options for the management of MDD and criteria used for treatment selection.